TALPHERA, INC. TLPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-49.59
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $28,000 | -$14.3M | — | — | $17.0M |
| 2024 | $0 | -$13.0M | — | -$12.7M | $8.0M |
| 2023 | $651,000 | -$18.4M | — | -$17.6M | $14.1M |
| 2022 | $0 | $47.8M | — | -$28.7M | $21.8M |
| 2021 | $2.8M | -$35.1M | — | -$31.8M | -$35.9M |
| 2020 | $5.4M | -$40.4M | — | -$40.4M | -$55.8M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -49.59 (distress)
- Working capital / assets 0.575
- Retained earnings / assets -15.866
- EBIT / assets -0.454
- Equity / liabilities 1.343
Source: SEC EDGAR filings · CIK 0001427925 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.